Long intergenic non-coding RNA APOC1P1-3 inhibits apoptosis by decreasing α-tubulin acetylation in breast cancer
1Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, No. 138 Yixueyuan Road, Shanghai, China.
Abstract:
Increasing evidence indicates that long non-coding RNAs (lncRNAs) act as important regulatory factors in tumor progression. However, their roles in breast cancer remain largely unknown. In present studies, we identified aberrantly expressed long intergenic non-coding RNA APOC1P1-3 (lincRNA-APOC1P1-3) in breast cancer by microarray, verified it by quantitative real-time PCR, and assessed methylation status in the promoter region by pyrosequencing. We also investigated the biological functions with plasmid transfection and siRNA silencing experiments, and further explored their mechanisms by RNA pull-down and RNA immunoprecipitation to identify binding proteins. We found that 224 lncRNAs were upregulated in breast cancer, whereas 324 were downregulated. The lincRNA-APOC1P1-3 was overexpressed in breast cancer, which was related to tumor size and hypomethylation in its promoter region. We also found that APOC1P1-3 could directly bind to tubulin to decrease α-tubulin acetylation, to inactivate caspase-3, and to inhibit apoptosis. This study demonstrates that overexpression of APOC1P1-3 can inhibit breast cancer apoptosis.
Insights
This study identifies long intergenic non-coding RNA APOC1P1-3 (lincRNA-APOC1P1-3) as overexpressed in breast cancer. Overexpression of lincRNA-APOC1P1-3 inhibits breast cancer cell apoptosis by affecting tubulin acetylation and caspase-3 activity.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- Long non-coding RNAs (lncRNAs) are increasingly recognized as crucial regulators in tumor development.
- The specific functions of lncRNAs in breast cancer pathogenesis are not yet fully understood.
Purpose of the Study:
- To identify and characterize aberrantly expressed lncRNAs in breast cancer.
- To elucidate the role and mechanism of lincRNA-APOC1P1-3 in breast cancer progression.
Main Methods:
- Microarray analysis to identify differentially expressed lncRNAs.
- Quantitative real-time PCR and pyrosequencing for validation and methylation analysis.
- In vitro functional assays (plasmid transfection, siRNA silencing) and molecular mechanism studies (RNA pull-down, RNA immunoprecipitation).
Main Results:
- Identified 224 upregulated and 324 downregulated lncRNAs in breast cancer.
- lincRNA-APOC1P1-3 was found to be overexpressed in breast cancer tissues, correlating with tumor size and promoter hypomethylation.
- lincRNA-APOC1P1-3 directly binds to tubulin, reducing α-tubulin acetylation, inactivating caspase-3, and consequently inhibiting apoptosis.
Conclusions:
- lincRNA-APOC1P1-3 is a significantly overexpressed lncRNA in breast cancer.
- Overexpression of lincRNA-APOC1P1-3 promotes breast cancer by inhibiting apoptosis through the regulation of tubulin acetylation and caspase-3 activity.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
The Intrinsic Apoptotic Pathway
MicroRNAs
MicroRNAs
The Extrinsic Apoptotic Pathway

